Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 60

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 60
---
 presentation at AAIC and an oral encore presentation at CTAD.

◦ Prasinezumab, a potential first-in-class antibody, for the treatment for Parkinson’s disease (PD), that is designed to target key epitopes within the C-terminus of alpha-synuclein and is the focus of the worldwide collaboration with Roche. In 2024, Roche reported results from the Phase 2b PADOVA clinical trial in patients with early-stage Parkinson’s disease missed the primary endpoint but showed a numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints suggesting possible clinical benefit. Roche announced that they will continue to evaluate the data and work together with health authorities to determine next steps.

◦ PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target, is part of the global neuroscience research and development collaboration with BMS. In 2024, Bristol Myers Squibb obtained the exclusive global license for PRX019 for $80 million; and Prothena initiated a Phase 1 first-in-human clinical trial to evaluate the safety, tolerability, immunogenicity, and pharmaco-kinetics of single ascending and multiple doses in healthy adults.

• We Made Significant Advances in our Rare Peripheral Amyloid Diseases Portfolio.

◦ Birtamimab, a wholly-owned potential best-in-class amyloid depleter antibody for the treatment of AL amyloidosis designed to directly neutralize soluble toxic light chain aggregates and promote clearance of amyloid that causes organ dysfunction and failure. In 2024, Prothena published Birtamimab’s mechanism of action and pharmacological characteristics in Leukemia & Lymphoma and presented Longitudinal Health-Related Quality of Life data (SF-36v2) across domains from the VITAL Phase 3 clinical trial at the International Society of Amyloidosis. We continued the confirmatory Phase 3 AFFIRM-AL clinical trial (NCT04973137) in patients with Mayo Stage IV AL amyloidosis under a Special Protocol Assessment (SPA) agreement with the

| 2025 PROXY STATEMENT |     | 35 |

TABLE OF CONTENTS

| COMPENSATION DISCUSSION AND ANALYSIS |

FDA with a primary endpoint of all cause mortality (time-to-event) at a significance level of 0.10.

◦ Coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody for the treatment of ATTR cardiomyopathy designed to